Welcome to our dedicated page for Relay Therapeutics news (Ticker: RLAY), a resource for investors and traders seeking the latest updates and insights on Relay Therapeutics stock.
Relay Therapeutics, Inc. (Nasdaq: RLAY) is a clinical-stage biotechnology company pioneering drug discovery through its Dynamo™ platform, which analyzes protein motion to develop precision therapies for oncology and genetic diseases. This page provides real-time access to official company announcements, research breakthroughs, and strategic developments.
Investors and industry professionals will find curated updates including clinical trial progress, regulatory milestones, and partnership announcements. All content is sourced directly from Relay Therapeutics’ communications and verified financial disclosures, ensuring reliability for decision-making.
Key coverage areas include innovations in small molecule therapeutics, updates on the Dynamo platform’s applications, and analyses of Relay’s position within the precision medicine landscape. Content is organized chronologically for easy tracking of the company’s evolution.
Bookmark this page to monitor Relay Therapeutics’ advancements in targeting historically undruggable proteins. For comprehensive insights into RLAY’s scientific and corporate developments, revisit regularly or subscribe to Stock Titan’s update alerts.
Relay Therapeutics (RLAY) reported its Q4 and full year 2024 financial results, highlighting progress in its breast cancer program. The company plans to initiate the Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant in mid-2025 for PI3Kα-mutated, HR+/HER2- metastatic breast cancer patients.
Key clinical data showed 11.4-month median PFS in second-line patients, with a 39% confirmed overall response rate and 67% Clinical Benefit Rate. The company ended Q4 2024 with $781.3 million in cash and investments, expected to fund operations into second half of 2027.
Financial results showed no revenue in Q4 2024, while full-year revenue decreased to $10.0 million from $25.5 million in 2023. R&D expenses were $68.1 million in Q4 2024, down from $77.5 million in Q4 2023. Net loss for Q4 2024 was $76.0 million ($0.45 per share), compared to $83.5 million ($0.67 per share) in Q4 2023.
Relay Therapeutics (RLAY), a clinical-stage precision medicine company, has announced its participation in two major investor conferences in March 2025. The company will be featured in fireside chat sessions at:
• TD Cowen's 45th Annual Health Care Conference on March 5, 2025, at 1:50 p.m. ET
• Barclays 27th Annual Global Healthcare Conference on March 11, 2025, at 11:00 a.m. ET
Both sessions will be accessible via live webcast through Relay Therapeutics' website in the News & Events section. Archived recordings will remain available for 30 days after each event. The company, known for combining computational and experimental technologies in drug discovery, makes these presentations available at https://ir.relaytx.com/news-events/events-presentations.
Relay Therapeutics (NASDAQ: RLAY), a clinical-stage precision medicine company, announced it will release its fourth quarter and full year 2024 financial results and corporate highlights on Wednesday, February 26, 2025, after U.S. market close. The company specializes in combining computational and experimental technologies for drug discovery.
Relay Therapeutics (RLAY), a clinical-stage precision medicine company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's President and CEO, Dr. Sanjiv Patel, will deliver a presentation on Tuesday, January 14, 2025, at 7:30 a.m. PT.
The presentation will be accessible through a live webcast on the company's website under the Events section in News & Events. Interested parties can access the webcast through the IR portal at ir.relaytx.com. An archived version of the presentation will remain available for 30 days after the event.
Relay Therapeutics specializes in transforming drug discovery by combining advanced computational and experimental technologies.
Relay Therapeutics (RLAY) announced updated interim data for RLY-2608, showing an 11.4-month median progression-free survival in second-line patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at the recommended Phase 2 dose. The study demonstrated a 39% confirmed objective response rate across all patients and 67% in patients with kinase mutations.
The drug showed a favorable tolerability profile, with 94% median dose intensity and mostly low-grade treatment-related adverse events. Among 64 patients at the recommended dose, only 31% experienced Grade 3 adverse events, with no Grade 4-5 events reported.
The company plans to initiate a pivotal Phase 2 study in 2025 and reported approximately $840 million in cash and investments as of Q3 2024.
Relay Therapeutics (RLAY) announced it will present updated clinical data for RLY-2608 in combination with fulvestrant for treating PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer at the San Antonio Breast Cancer Symposium (December 10-13, 2024). The presentation, titled 'Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial', will be part of a poster spotlight session on targeting ER and PI3K pathway. The company will host a conference call on December 11, 2024, at 7:00 a.m. ET to discuss the findings.
Relay Therapeutics (RLAY) and Elevar Therapeutics have announced an exclusive global licensing agreement for lirafugratinib, a potential best-in-class FGFR2 inhibitor for treating FGFR2-driven cholangiocarcinoma and other solid tumors. Under the agreement, Elevar receives worldwide development and commercialization rights, while Relay can earn up to $500 million in payments, including $75 million in upfront and regulatory milestones, plus up to double-digit royalties on global sales. The FDA has granted lirafugratinib breakthrough therapy and orphan drug designations, and recommended filing an NDA for FGFR2-driven CCA first, followed by a supplemental NDA for other solid tumors.
Relay Therapeutics (Nasdaq: RLAY) has announced its participation in four upcoming investor conferences in November and December 2024. The company will participate in fireside chats at the Guggenheim Healthcare Innovation Conference (Nov 13), Stifel Healthcare Conference (Nov 18), Jefferies London Healthcare Conference (Nov 20), and Citizens JMP Hematology and Oncology Summit (Dec 2). All sessions will be webcast live and accessible through Relay's website, with recordings available for 30 days after each event.
Relay Therapeutics reported its third quarter 2024 financial results and corporate highlights. Key highlights include interim data for RLY-2608 + fulvestrant showing a 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer. The company plans to initiate a pivotal trial in 2025.
Relay Therapeutics has $840 million in cash, expected to fund operations into the second half of 2027. Revenue for Q3 2024 was $0, down from $25.2 million in Q3 2023. R&D expenses decreased to $76.6 million, while G&A expenses increased to $19.8 million. The net loss was $88.1 million, or $0.63 per share.
Corporate highlights include a $230 million follow-on offering and a $50 million annual savings from streamlining the research organization. Looking ahead, the company plans several clinical trial initiations and expansions in 2024 and 2025.
Relay Therapeutics (Nasdaq: RLAY), a clinical-stage precision medicine company, announced it will report its third quarter 2024 financial results and corporate highlights on November 6, 2024 after the U.S. financial markets close.
